CYP2C19 and graft versus host disease: There were no significant differences between the two groups with respect to age, sex, body weight, POR genotype, CYP2C19 genotype, diagnosis, donor type, stem cell source, human leukocyte antigen (HLA) disparity, conditioning regimen, GVHD prophylaxis, concomitant antifungal agents, or levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (T-Bil), or Scr.